{"name":"DKMS gemeinnützige GmbH","slug":"dkms-gemeinn-tzige-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HAM","genericName":"HAM","slug":"ham","indication":"Mobilization and collection of hematopoietic stem cells for autologous stem cell transplantation in hematologic malignancies","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"LDAC and/or Mitoxantrone","genericName":"LDAC and/or Mitoxantrone","slug":"ldac-and-or-mitoxantrone","indication":"Acute myeloid leukemia (AML), particularly in elderly or unfit patients","status":"phase_3"}]}],"pipeline":[{"name":"HAM","genericName":"HAM","slug":"ham","phase":"marketed","mechanism":"HAM is a hematopoietic stem cell mobilization and collection system used to facilitate autologous stem cell transplantation.","indications":["Mobilization and collection of hematopoietic stem cells for autologous stem cell transplantation in hematologic malignancies","Support for high-dose chemotherapy with stem cell rescue"],"catalyst":""},{"name":"LDAC and/or Mitoxantrone","genericName":"LDAC and/or Mitoxantrone","slug":"ldac-and-or-mitoxantrone","phase":"phase_3","mechanism":"LDAC (low-dose cytarabine) and mitoxantrone are chemotherapy agents that inhibit DNA synthesis and topoisomerase II, respectively, to kill rapidly dividing leukemic cells.","indications":["Acute myeloid leukemia (AML), particularly in elderly or unfit patients","Relapsed or refractory acute leukemia"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}